Financial terms of the acquisition were not disclosed.
Walk Vascular designed its JETi peripheral thrombectomy system and the next-generation JETi AIO (all-in-one) peripheral thrombectomy system to remove intravascular peripheral blood clots that can reduce blood flow and lead to serious complications for patients.
The company designed the JETi systems with the capabilities to break up and remove clots from the peripheral vascular system while reducing the risk of dislodged clots. Both JETi systems have garnered FDA 510(k) clearance and CE mark and the company is currently enrolling up to 250 patients in the U.S. and Europe in the JETi Registry.
According to a news release, Abbott will incorporate Walk Vascular’s peripheral thrombectomy systems into its existing endovascular product portfolio.
“The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott’s ability to provide one-of-a-kind endovascular therapy solutions to improve patient care,” SVP of Abbott’s vascular business Julie Tyler said in the release. “Walk Vascular’s technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care.”